Factors influencing receipt of adjuvant chemotherapy after surgery for pancreatic cancer: a two-center retrospective cohort study
Authors:
- 6 September 2016
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 52 (1) , 56-60
Abstract
The addition of adjuvant chemotherapy after surgical resection has improved survival rates for patients with pancreatic ductal adenocarcinoma (PDAC). However, outside clinical trials, many operated patients still do not receive adjuvant chemotherapy due to clinical and tumor-related factors. The aim of this study was to investigate factors that may influence the receipt of adjuvant chemotherapy and the effect on long-term survival. Patients undergoing macroscopically curative resection for PDAC at the University Hospitals in Lund and Linköping, Sweden, between 1 January 2007 and 31 December 2015, were retrospectively reviewed. Clinical and pathological data were compared between adjuvant and non-adjuvant chemotherapy groups and factors affecting chemotherapy receipt were analyzed by multiple logistic regression. Multivariable Cox regression analysis was performed to select predictive variables for survival. A total of 233 patients were analyzed. Adjuvant chemotherapy was administered to 167 patients (71.7%). The likelihood of receiving adjuvant chemotherapy decreased with age, OR 0.91, 95% CI 0.86-0.95, p < .001. Moreover, patients with severe postoperative complications (Clavien-Dindo grade ≥ III) were less likely to receive adjuvant chemotherapy, OR 0.31, 95% CI 0.14-0.71, p = .005. The presence of lymph node metastases on histopathological reporting was associated with increased likelihood of initiating adjuvant chemotherapy, OR 2.19, 95% CI 1.09-4.40, p = .028. Adjuvant chemotherapy was an independent factor for prolonged survival on multivariable Cox regression analysis, HR 0.45 (95% CI 0.31-0.65), p < .001. Age, postoperative complications and the presence of lymph node metastases affect the likelihood of receiving adjuvant chemotherapy after PDAC surgery.Keywords
This publication has 34 references indexed in Scilit:
- Pancreatic Ductal AdenocarcinomaAnnals of Surgery, 2013
- Multidisciplinary Management of Cancer Patients: Chasing a Shadow or Real Value? An Overview of the LiteratureCurrent Oncology, 2012
- Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III TrialAnnals of Surgical Oncology, 2011
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- Complications and mortality in older surgical patients in Australia and New Zealand (the REASON study): a multicentre, prospective, observational study*Anaesthesia, 2010
- Impact of Selection Bias on the Utilization of Adjuvant Therapy for Pancreas AdenocarcinomaAnnals of Surgical Oncology, 2009
- Assessment of Pancreatic Cancer Care in the United States Based on Formally Developed Quality IndicatorsJNCI: Journal of the National Cancer Institute, 2009
- Pre-operative risk scores for the prediction of outcome in elderly people who require emergency surgeryWorld Journal of Emergency Surgery, 2007
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerNew England Journal of Medicine, 2004